The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has initiated a worldwide response aiming to contain the virus and the global spread. Research worldwide has led to the development of vaccines aiming to build up global protection from the virus however, an alternative, less invasive method has been suggested that includes the use of antiviral medications in the form of nasal sprays, as a way of protection from the virus or as a method to block the virus at its first replication site, which is found in the upper respiratory system. Yet, up to date, no reliable method has been established for nasal sprays or other similar methods, which would allow the infusion of the solution into the paranasal sinuses.
A new medical device that can be applied to any population, Igmorino® is suggested as a potential new approach for microbial and viral infections of the upper respiratory tract, which could include COVID-19, as it can reach nasal cavities and paranasal sinuses. NAUMED® Ltd. under the scientific overview of SR21 – Institute for Scientific Research, Zurich, conducts an ongoing pilot study that has already tested the device in 32 patients (ongoing-more patients will be included) who were tested positive for COVID-19.
Igmorino® device containing NaCl solution was provided to the patients following a positive RT-PCR COVID-19 test. Results demonstrated a statistical significance in Ct values following the application of Igmorino® which suggests that it may reduce the intensity, extent, and duration of the disease, accelerate healing and prevent hospitalization. In addition, the results of the study have shown that the median time from diagnosis to the first negative RT-PCR conversion occurs within 6 days of Igmorino® applications, while a rapid viral load reduction has been observed in all patients along with significant improvements in the clinical condition from the very first applications of Igmorino® (in the first 24 hours). It should also be pointed out that positive COVID-19 patients that followed the Igmorino® method, experienced no post-COVID-19 side effects (long COVID).